PATIENT STORIES: THE USE OF NOVEL ANTI-FIBROTICS, PIRFENIDONE AND NINTEDANIB, IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS, IPF

被引：0
|
作者：
Enston-Newall, S. [1 ]
机构：
[1] Cardiff Univ, Cardiff, S Glam, Wales
来源：
THORAX | 2017年 / 72卷
关键词：
D O I：
10.1136/thoraxjnl-2017-210983.443
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M21
引用
收藏
页码：A247 / A248
页数：2
相关论文
共 50 条
  • [41] Pirfenidone and Nintedanib Therapy for Idiopathic Pulmonary Fibrosis: A Tertiary Centre Experience
    Diab, N.
    Mao, T.
    Danoff, S. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [42] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
    Lehtonen, Siri T.
    Veijola, Anniina
    Karvonen, Henna
    Lappi-Blanco, Elisa
    Sormunen, Raija
    Korpela, Saara
    Zagai, Ulrika
    Skold, Magnus C.
    Kaarteenaho, Riitta
    RESPIRATORY RESEARCH, 2016, 17
  • [43] Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Belhassen, Manon
    Dalon, Faustine
    Nolin, Maeva
    Van Ganse, Eric
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [44] Comparative Effectiveness of Nintedanib and Pirfenidone in Patients Diagnosed With Idiopathic Pulmonary Fibrosis
    Shankar, D.
    Law, A.
    Walkey, A. J.
    Hawkins, F. J.
    Alysandratos, K.
    Wilson, K. C.
    Bosch, N. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [45] Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Manon Belhassen
    Faustine Dalon
    Maëva Nolin
    Eric Van Ganse
    Respiratory Research, 22
  • [46] Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
    Dempsey, Timothy M.
    Payne, Stephanie
    Sangaralingham, Lindsey
    Yao, Xiaoxi
    Shah, Nilay D.
    Limper, Andrew H.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (07) : 1121 - 1128
  • [47] Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis
    Hogben, C.
    Kouranos, V.
    Kokosi, M.
    Renzoni, E. A.
    Chua, F.
    Wells, A. U.
    Maher, T. M.
    Molyneaux, P. L.
    George, P. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [48] Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
    Bonniaud, Philippe
    Cottin, Vincent
    Spagnolo, Paolo
    Nolin, Maeva
    Dalon, Faustine
    Kirchgassler, Klaus-Uwe
    Chia, Jenny
    Kamath, Tripthi
    Van Ganse, Eric
    Belhassen, Manon
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [49] Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis
    Corral, Mitra
    Chang, Eunice
    Broder, Michael S.
    Gokhale, Sohum
    Reddy, Sheila R.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (13) : 933 - 943
  • [50] Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
    Cottin, Vincent
    Spagnolo, Paolo
    Bonniaud, Philippe
    Dalond, Faustine
    Nolind, Maeva
    Kirchgassler, Klaus-Uwe
    Van Ganse, Eric
    Belhassen, Manon
    RESPIRATORY MEDICINE AND RESEARCH, 2023, 83
12345